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In this study, we investigated the protective effects of Hedera nepalensis crude extract, its fractions 
and lupeol in alloxan-induced diabetic rats. Lupeol and n-hexane (HNN) fraction significantly reduced 
the blood glucose level by increasing insulin level in time dependent manner, and also significantly 
increased amylase and lipase activity in diabetic rats. Elevated levels of alanine transaminases (ALT), 





), total bilirubin and total protein in blood serum were efficiently restored to normal levels. 
Suppressed enzymatic activity of catalase (CAT), superoxide dismutase (SOD), reduced glutathione 
(GSH) and peroxidase (POD) were also restored to their normal levels. Kidney functions were also 
restored to normal level after treatment with HNN and lupeol. HNN fraction and lupeol of H. nepalensis 
prevented oxidative stress in alloxan-induced diabetic rats. This study signifies the importance of H. 
nepalensis and lupeol in ameliorating diabetes by inducing insulin secretion in diabetic model rats.
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INTRODUCTION 
Diabetes Mellitus (DM) is a metabolic disorder 
characterized by high blood glucose concentration 
(hyperglycaemia) due to insufficient secretion of 
insulin from pancreatic β-cells (Jarald, Joshi, Jain, 
2008). Glycogen breakdown exacerbates due to low 
insulin secretion, leading to low hepatic glycogen level. 
Abnormal glycogen metabolism causes overexpression 
of the liver marker enzymes: transaminases and 
phosphatases (Amarapurkar, Das, 2001). Diabetes causes 
oxidative stress that acts to change cellular physiology, 
with decreased level of catalase (CAT), renal superoxide 
dismutase (SOD) and reduced glutathione (GSH) (Tiwari 
et al., 2013). Oxidative stress has been implicated as major 
factor leading to pathogenesis and complication of diabetes 
(Nakhjavani et al., 2013). Liver is the most affected organ 
in chronic diabetes (Leclercq et al., 2007). Globally, about 
170 million people are diabetic, and it is estimated that this 
figure will double by 2030 (Marx, 2002). Development of 
new therapies to ameliorate DM is a hot research area.
Since beginning of human civilization, plants 
extracts have been used to treat various ailments. To date, 
about 50% of all medicines in clinical trial for evaluation 
are extracted from natural product (derivatives or 
analogs), and plants contribute more than 25% of all 
therapeutic agents (Gurib-Fakim, 2006). Secondary 
metabolites of plants are preferred over synthetic 
compounds as drugs, because they are more biological 
friendly and effective within living system. In Asia and 
Africa, herbs proven to be medicinally important for 
diabetes have been used for centuries. Inspite of little 
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scientific evidence for use of plant based medicine, 
traditional plant drugs have been used because of their 
minimal side effects and low cost (Ismail, Mirza, 2015). 
Genus Hedera (family Araliaceae) is distributed 
in North Europe, Asia, China, Japan and North Africa. 
Many species of genus Hedera are present in Northern 
areas of Pakistan. Hedera nepalensis is among one of 
the most valuable plants to treat different diseases. It 
has spasmolytic, sedative, antihelmintic, molluscicidal, 
antileishmanial and antifungal properties (Xue, ZhiYing, 
2010). Catechin and caffeic acid have been reported 
in ethyl acetate fraction of H. nepalensis, along with 
phenolic compounds that have promising antioxidant 
activity (Jafri et al., 2014). The plant is also effective 
against tumour cells (Hamayun et al., 2006). In vitro 
biological activities, including brine shrimp cytotoxicity, 
potato disc antitumor activity and phytotoxic activity 
exhibited promising results (Inayatullah et al., 2007). 
The phytochemical analysis of H. nepalensis showed the 
presence of alkaloids, flavonoids, steroids, tannins and 
terpenoids (Kanwal et al., 2011). 
H. nepalensis has been reported in literature as 
a natural folk medicine, particularly for the treatment 
of diabetes (Ríos, Francini, Schinella, 2015) in the 
subcontinent. Akhtar et al. (2013) reported that juice 
from leaves of H. nepalensis is used to cure diabetes 
and to purify blood. Dried branches and leaves of H. 
nepalensis are grinded and the powder is used early 
in the morning with water against diabetes in the 
temperate Himalayan region (Begum et al. 2014). Here 
we evaluate the hypoglycaemic and in vivo antioxidant 
activity of H. nepalensis crude extract (HNC) and 
fractions (HNN, HNE and HNA), along with one 
purified compound lupeol. 
MATERIAL AND METHODS 
Plant collection 
The plant H. nepalensis under the local name of 
Bumbar was collected in September 2016 from Nathia 
Gali (District Rawalpindi, Punjab, Pakistan). The 
Plant was taxonomically identified by Dr. Rizwana 
Aleem Qureshi, Department of Plant Science, Faculty 
of Biological Sciences, Quaid-i-Azam University, 
Islamabad. Plant specimen was deposited under the 
voucher specimen HMP-461 in the “Herbarium of 
medicinal plants of Pakistan”, Quaid-i-Azam University, 
Islamabad, Pakistan.
Preparation of plant extract and isolation of lupeol
Plant material was dried under shade, ground into fine 
powder and then macerated in methanol and chloroform 
mixture (1:1). The eluted solution was concentrated 
in rotary evaporator (Buchi, Switzerland) to get H. 
nepalensis crude extract (HNC). The suspension of HNC 
obtained after mixing in hot distilled water, was subjected 
to partition three times with n-hexane. HNN (n-hexane) 
fraction obtained after concentrating with rotary evaporator 
yielded residual aqueous portion that was used to partition 
three times with ethyl acetate solution followed by rotary 
evaporation to get HNE fraction. Similarly, residual 
aqueous layer produced HNA fraction after concentrating 
in rotary evaporator. These extracts were stored at -20 °C 
for further studies. Lupeol was isolated previously by our 
research group (Saleem et al., 2014) as a white powder 





O (m/z 426.72) as suggested by mass spectral data. 
Lupeol solution was prepared as 5 mg/kg BW dissolved in 
10% DMSO for experiments. 
Animal maintenance
Male Sprague-Dawley rats weighing 200-250 g 
were chosen for in-vivo assays. They were kept in 
aluminium cages maintained in ventilated room with 
free access to food and tap water. The study protocols 
were approved by Ethical Committee of Quaid-i-Azam 
University, Islamabad. All experiments were conducted 
in accordance with the National Biosafety Guideline. 
Maximum dose tolerance test
For chemical testing, the acute toxicity studies were 
performed as per the guidelines 425 of Organization 
for Economic Cooperation and Development (OECD) 
(OECD, 2001). For this purpose, the rats were subjected 
to various doses of the extracts (125, 250, 500, 750 
and 1000 mg/kg BW) orally along with saline solution 
(10 mL/kg) as control. Any mortality, toxicity and 
behavioural changes were monitored for one week after 
oral administration. 
Induction of diabetes 
Diabetes was induced in rats by a single 
intraperitoneal injection (0.2 mL) of 120 mg/kg of 
alloxan monohydrate dissolved in DMSO. After 48 
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hours, blood was taken from tail of the rats kept on 
fasting for 9 hours (only 10% glucose solution diet). 
Glucose level was determined to confirm the induction 
of diabetes using test strips in Lifescan one touch Vita™ 
test meter. Diabetic rats with glucose level > 300 mg/dL 
were used for further experiments. 
Treatment groups and antidiabetic study
Total fifty-six Sprague-Dawley male rats were 
randomly distributed into eight groups, each group 
containing seven rats. Group-I (NC, normal control, 
non-diabetic) received 10% DMSO administered orally 
(10 mL/kg BW/day). Group-II (DC, diabetic control) 
received 10% DMSO per day orally. Group-III (DC+HNC) 
received crude extract. Group-IV (DC+HNN) received 
n-hexane fraction. Group-V (DC+HNE) received ethyl 
acetate fraction. Group-VI (DC+HNA) received aqueous 
fraction. Group VII (DC+lupeol) received lupeol orally 
at 5 mg/kg BW/day dissolved in 10% DMSO. Group 
VIII (DC+glibenclamide) received glibenclamide orally 
at 5 mg/kg BW/day as standard drug dissolved in 10% 
DMSO. All the experimental  groups were fed orally at 
400 mg/kg BW/day of extract dissolved in 10% DMSO. 
The treatments were carried out for 14 consecutive days. 
Glucose level was determined on day 0 at 0 h, 0.5 h, 1 h, 
2 h and 4 h and day 3, 6, 9, 12, 15 from rats blood taken 
from tail vein using test strips in Lifescan one touch 
Vita™ test meter. 
Serum and tissue preparation 
On day 15, after glucose determination, the rats 
were anesthetized with chloroform and sacrificed to get 
blood by cardiac puncture. The blood was collected in 
BD Vacutainer® tubes and then centrifuged at 3500 
rpm for 10 min to separate the serum. Kidney, heart, 
liver and pancreas were separated from the rats, washed 
thoroughly with saline and stored at -20 ºC for future use. 
Determination of biochemical markers 
of pancreas, liver, kidney and heart
Pancreatic enzymes such as amylase and lipase 
were estimated in the serum of treated animals according 
to the guidelines mentioned on supplier’s standard 
kits levels using the Cobas® kits (Roche Diagnostics, 
Indianapolis, IN, USA). Quantitative estimation of 
insulin in rat serum was accomplished with the help 
of an enzyme-linked immunosorbent assay (ELISA) 
using a commercial kit (Micro LISA Insulin Amgenix, 
USA) according to the protocol provided in the kit. 
Biochemical markers such as ALT, AST, total bilirubin, 
total protein, creatinine and BUN were estimated in 
the serum acquired from the treated animals according 
to the guidelines mentioned on supplier’s standard 
kits levels using the Cobas® kits (Roche Diagnostics, 
Indianapolis, IN, USA). 
Determination of antioxidant markers
Tissue parts (100 mg) of heart, kidney, liver and 
pancreas of every animal were homogenized in ice cold 
50 mM tris buffer (pH 7.4) and centrifuged at 10,000 
rpm for 30 min at 4 °C. The supernatant was analysed 
for CAT, SOD, protein estimation, POD, TBARS, GSH, 
nitrite and hydrogen peroxide as detailed below:
CAT activity
CAT activity was measured following Aebi 
(1984) with slight modifications. The reaction mixture 
comprised of 2.5 mL of 50 mM phosphate buffer (pH 5.0), 




 and 0.1 mL tissue homogenate. 
After 1 min, absorbance was calculated at 240 nm using 
microtitre plate reader and results were represented as 
U/min. Total protein was measured using the Bradford 
method at 650 nm.
SOD activity
SOD activity was analysed by the method of 
Bannister and Calabrese (2006). Reaction mixture 
contained 0.1 mL of phenazine methosulphate (186 μM), 
1.2 mL of phosphate buffer (pH 7.0) and 0.3 mL of tissue 
sample followed by the addition of 0.2 mL of NADH 
(780 μM). After 1 min, 1 mL of glacial acetic acid was 
added to stop reaction and absorbance was measured at 
560 nm. The SOD activity is expressed as U/mg protein.
POD activity
POD activity was measured following Khan et al. 
(2015), with some modification. The reaction mixture 
contained 625 μL of 50 mM phosphate buffer (pH 5.0), 
25 μL of 20 mM guaiacol, 25 μL of tissue sample and 




. Absorbance was measured at 
470 nm. The POD activity is expressed as U/min protein
Waleed Javed Hashmi, Hammad Ismail, Laila Jafri, Bushra Mirza
Page 4/15 Braz. J. Pharm. Sci. 2020;56: e18406
TBARS activity
Lipid peroxidation (TBARS) activity was performed 
in tissue homogenate according to Ohkawa et al. (1979). 
The samples were mixed with phosphate buffer (0.1 M; 
pH 7.4) in 1:4 ratio followed by incubation at 37 °C in 
a shaking water bath for 1 hour. Reaction mixture was 
prepared by adding 10% trichloroacetic acid and working 
reagent TBA (5% acetic acid and 20% sodium hydroxide) 
with sample solution. All the reaction mixtures were 
placed in a boiling water bath for 20 min followed by ice 
bath treatment for 10 min and centrifuged at 10,000 ×g for 
10 min. The supernatant was used to measure absorbance 
at 532 nm in a clear 96-well microplate using microtitre 
plate reader against a reagent blank. The results were 










 level in tissue homogenate was measured 
following Pick and Keisari (1981). Reaction mixture 
containing 100 μL of tissue homogenate, 100 μL of 
0.28 nM phenol red, 500 μL of 0.05 M potassium 
phosphate buffer (pH 7.0), 250 μL of 5.5 nM dextrose 
and 8 units of horse radish peroxidase was incubated at 
37°C for 40 min. After this incubation step, 100 μL of 
10 N NaOH was mixed in tubes to stop reaction, followed 
by centrifugation at 800 g for 15 minutes. Supernatant 





activity was expressed in nM/min/mg tissue.
GSH activity
Tissue homogenate (1 mL) and sulfosalicylic acid 
(1 mL) were mixed, kept at 4 °C for 1 hour and centrifuged 
at 1200 ×g for 20 min at 4 °C. The final volume of 3 
mL reaction mixture contained 2.7 mL phosphate 
buffer (0.1 M; pH 7.4), 0.1 mL filtered solution and 
0.2 mL DTNB (100 mM) followed by measurement of 
absorbance at 412 nm (Ellman, 1959). The GSH activity 
is expressed as mM/g protein 
NO activity
NO− 2/NO− 3 levels were estimated colorimetrically 
in tissue samples, following Berkels et al. (2004). The Griess 
reaction was used to determine nitrite and nitrate levels 
thereby allowing chemical reaction between sulfanilamide 
and N-1-naphthylethylenediamine dihydrochloride under 
acidic condition. Resulting bright reddish-purple colored 
azo-compound was quantified at 540 nm. By using 
standard curve of sodium nitrite, NO concentration was 
calculated. Nitrite activity was presented as μMol/mL.
Histopathological analysis
For histopathological analysis tissues were excised 
from slaughtered animals and were immediately washed 
with saline and fixed in a fixative (absolute ethanol 
60%, formaldehyde 30% and glacial acetic acid 10%) 
and embedded in paraffin wax after xylene washing. 
Sections of 5 μm thickness were cut by microtome and 
allowed to stain with hematoxylin-eosin. Sections were 
examined under light microscope (DIALUX 20 EB) at 
10X and 40X. Slides of all groups were photographed 
with examination of minimum 14 fields of each section.
Statistical analysis
The results were evaluated by one-way ANOVA 
followed by Dunnett’s multiple-comparison test by using 
GraphPad Prism 5.0 software. The results were stated as 
mean ± SEM (standard error mean). Differences were 
reflected to be statistically significant at p < 0.05.
RESULTS
Dose tolerance test 
No mortality was recorded in the experimental 
animals at any dose from 100 mg/kg BW upto maximum 
of 1000 mg/kg BW. Consequently, 400 mg/kg BW of the 
maximum dose was considered as optimal dose for the 
antidiabetic study. 
Hypoglycemic activity of H. nepalensis 
extracts and lupeol in diabetic rats
The diabetic control group showed glucose 
range of 399 ± 9.3 to 508 ± 3.6 mg/dL during the 
15 days experiment (Table I). The glucose level in 
glibenclamide group was significantly (p < 0.005) 
lowered to 80.2% on 15th day when compared to day 0 
(Figure 1). The crude extract of H. nepalensis produced 
55.1% reduction in the blood glucose level of diabetic 
rats while among the fractions, HNN resulted in 70.0% 
decrease in the level of blood glucose (Figure 1). 
Glucose level was lowered from 340 ± 4.1 mg/dL 
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on day 0 to 105 ± 3.2 mg/dL on day 15 in lupeol 
group (Table I; Figure 1). Whereas HNE and HNA 
also showed a reduction in elevated glucose level upto 
maximum of 32.0% and 34.6% respectively. 
TABLE I - Effect of H. nepalensis extracts and lupeol on blood glucose level (mg/dL) in alloxan induced diabetic rats
Groups 0 h 0.5 h 1 h 2 h 4 h 3rd day 5th day 9th day 12th day 15th day
DC 399 ± 9.3 505 ± 4.5 508 ± 3.6 496 ± 3.8 490 ± 4.0 495 ± 2.9 490 ± 4.3 492 ± 3.1 493 ± 2.0 499 ± 3.8
NC 98 ± 3.9* 91 ± 3.3* 97 ± 6.4* 101 ± 3.1** 93 ± 5.5* 92 ± 2.8** 95 ± 3.3* 92 ± 4.1* 94 ± 1.8** 96 ± 4.0**
DC+HNC 401 ± 11.7NS 425 ± 13.2 NS399 ± 12.5 NS 289 ± 9.1NS 248 ± 17.9NS 250 ± 4.7* 265 ± 5.5* 255 ± 3.3** 225 ± 4.2* 224 ± 4.9*
DC+HNN 400 ± 6.19* 254 ± 4.7** 201 ± 2.4** 179 ± 4.0** 159 ± 4.3** 155 ± 2.5** 149 ± 3.8** 154 ± 2.2* 148 ± 2.2** 150 ± 2.4*
DC+HNE 394 ± 5.3NS 362 ± 10.9NS 345 ± 6.4* 333 ± 9.9NS 343 ± 6.1* 348 ± 4.3* 340 ± 4.9* 342 ± 4.8* 335 ± 3.3* 343 ± 3.9**
DC+HNA 407 ± 4.2 NS 455 ± 28.6 NS 402 ± 6.7* 356 ± 9.1NS 365 ± 6.5* 358 ± 5.6* 339 ± 3.7** 322 ± 3.6** 346 ± 4.1* 365 ± 4.7*
DC+lupeol 389 ± 6.1* 225 ± 3.9** 159 ± 4.3** 128 ± 3.7** 108 ± 4.6** 106 ± 2.6** 108 ± 2.7* 110 ± 2.9* 102 ± 2.4** 105 ± 3.2**
DC+Gilb 373 ± 3.2* 185 ± 3.5** 128 ± 2.1** 109 ± 3.2** 101 ± 3.9** 103 ± 2.3** 101 ± 1.4** 102 ± 2.2* 101 ± 1.9** 99 ± 3.6**
Where “NC” is normal control, “DC” is diabetic control, “HNC” is H. nepalensis crude extract, “HNN” is H. nepalensis 
n-hexane fraction, “HNE” is H. nepalensis ethyl acetate fraction, “HNA” is H. nepalensis aqueous fraction and “Gilb” is 
glibenclamide served as positive control. Values are * p < 0.05 and ** p < 0.01 statistically significant as compared to diabetic 
control group expressed as means ± SEM whereas NS represents non-significant.
FIGURE 1 - Change (percent) in blood glucose level of alloxan induced diabetic rats on different timeline. Values are significant 
at *p<0.05 as compared to diabetic control group expressed as means. Where “NC” is normal control, “DC” is diabetic control, 
“HNC” is H. nepalensis crude extract, “HNN” is H. nepalensis n-hexane fraction, “HNE” is H. nepalensis ethyl acetate 
fraction, “HNA” is H. nepalensis aqueous fraction and “Gilb” is glibenclamide served as positive control.
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Effects of HNC, HNN, HNE, HNA and lupeol 
on pancreatic activity in blood serum
The effects of glibenclamide, lupeol, H. nepalensis 
crude extract and fractions on various pancreatic 
enzymes of diabetic rats are presented in the Figure 2. 
Normalization of insulin level is represented in Figure 
2a with subsequent treatment of glibenclamide, extracts 
and lupeol on 15 days. Most significant (p < 0.05) results 
were depicted by HNN and lupeol treatment. Plasma 
insulin level decreased in diabetic control, which shows 
negative impact of decrease in activity as compared to 
amylase and lipase. Increase in plasma insulin level 
was increasing in rats treated with HNN and lupeol. 
Elevated amylase and lipase level in diabetic rats also 
decreased by the extracts and fractions of H. nepalensis 
as compared to diabetic control (Figure 2b). HNN 
showed moderate while lupeol exhibited significant (p < 
0.05) reduction in glucose level compared to the normal 
control and glibenclamide group.
FIGURE 2 - (a) insulin level (b) amylase and lipase level after 15 days of treatment. Values are *p<0.05 and **p<0.01 statistically 
significant as compared to positve control group expressed as means. Where “NC” is normal control, “DC” is diabetic control, 
“HNC” is H. nepalensis crude extract, “HNN” is H. nepalensis n-hexane fraction, “HNE” is H. nepalensis ethyl acetate 
fraction, “HNA” is H. nepalensis aqueous fraction and “Gilb” is glibenclamide served as positive control.
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Effects of HNC, HNN, HNE, HNA and lupeol on liver, 
kidney and heart biomarkers in blood serum
H. nepalensis crude extract and fractions were 
tested to determine levels of different biomarkers (total 
protein, total bilirubin, ALT, AST, BUN, creatinine) 
altered due to induction of alloxan. A significant change 
in levels of these biomarkers was observed in diabetic 
rats in comparison to that of the normal control rats 
(Table II). In case of liver, elevated level of ALT, AST, 
total bilirubin and total protein level of diabetic rats 
were decreased by the effect of extract and fractions in 
comparison to diabetic control (Table II). In particular, 
HNN and lupeol showed a significant (p < 0.05) decrease 
of 35.1% and 60.4% in ALT level, respectively. Similar 
pattern for decreased level of AST (HNN: 50.1% and 
lupeol: 63.7%), total bilirubin (HNN: 45.8% and lupeol: 
29.2%) and total protein level (HNN: 39.0% and lupeol: 
25.6%) was observed as compared to diabetic control. 
High biochemical parameters of kidney (creatinine 
and BUN) were decreased on treatment with different 
extracts and lupeol. Promising decrease in levels was 
shown by HNN and lupeol in both tests as compared 
to other groups (Table II). Figure 3 represents the 
percentage of the all biochemical parameters calculated 
from diabetic control group. 




NC DC DC+HNC DC+HNN DC+HNE DC+HNA DC+lupeol DC+Gilb
Liver
ALT (U/L) 22.1 ± 2.4* 57.3 ± 2.1* 35.2 ± 8.8NS 37.2 ± 1.6 ** 31.2 ± 7.8NS 30.5 ± 3.5* 22.7 ± 0.9 ** 23.6 ± 1.5




0.35 ± 0.05* 1.20 ± 0.04* 0.71 ± 0.06* 0.65 ± 0.02** 0.65 ± 0.07* 0.61 ± 0.05* 0.85 ± 0.02** 0.38 ± 0.01
Total protein  
(G/dl)




19.5 ± 0.8** 35.5 ± 1.5* 32.2 ± 1.9* 25.6 ± 1.4** 31.6 ± 1.8* 28.4 ± 1.1** 23.2 ± 1.0** 21 ± 1.2
Creatinine  
(mg/dL)
0.37 ± 0.04* 1.61 ± 0.03** 1.22 ± 0.02** 0.75 ± 0.01** 1.25 ± 0.05* 0.92 ± 0.02** 0.56 ± 0.02** 0.5 ± 0.01
Where “NC” is normal control, “DC” is diabetic control, “HNC” is H. nepalensis crude extract, “HNN” is H. nepalensis 
n-hexane fraction, “HNE” is H. nepalensis ethyl acetate fraction, “HNA” is H. nepalensis aqueous fraction and “Gilb” is 
glibenclamide served as positive control. Values are * p < 0.05 and ** p < 0.01 statistically significant as compared to positive 
control group expressed as means ± SEM whereas NS represents non-significant.
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FIGURE 3 - Percentages of biochemical parameters after 15 days of treatment. Where “NC” is normal control, “DC” is diabetic 
control, “HNC” is H. nepalensis crude extract, “HNN” is H. nepalensis n-hexane fraction, “HNE” is H. nepalensis ethyl acetate 
fraction, “HNA” is H. nepalensis aqueous fraction and “Gilb” is glibenclamide served as positive control.
Effect of H. nepalensis and lupeol on tissue 
protein, H2O2, TBARS and nitrite contents 





, TBARS and nitrite contents in 
diabetic control group (Table III). H. nepalensis crude 
extract, its fractions and lupeol exhibited significant 
(p < 0.05) reduction against elevated level of above 
mentioned parameters at various potential. TBARS 
level was restored to normal level of 30.4 nM/min/mg 
in pancreas, 35.1 nM/min/mg in liver and 29.9 nM/
min/mg in kidneys, (diabetic controls contained upto 
60.5 nM/min/mg tissue). When diabetic rats were 
treated with HNN, decreased in TBARS activity of 
kidney (51.7%), liver (27%) and pancreas (37.4%) was 
recorded. Lupeol significantly reduced TBARS level: 
41.1% (liver), 46.6% (kidney) and 46.5% (pancreas). 
Hydrogen peroxide activity was also reduced in liver 
(28.3%), kidney (19.5%) and pancreas (40.2%) of HNN 





for liver (29.6%), kidney (21.9%) and pancreas (43.8%) 
as compared to diabetic control. Decrease in in vitro 
nitrite content of organ especially liver and pancreas as 
compared to diabetic control was observed to the level 
of 25.2% and 20.2% for respective organs, when treated 
with HNN. Lupeol showed decrease of 29.4% for liver 
and 16.6% for pancreas as compared to diabetic control. 
H. nepalensis and lupeol treatment notably restored the 
contents which were prominently significant (p < 0.05) 
when compared to that of the diabetic control group.
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DC 12 ± 0.41* 43.6 ± 0.17** 4 ± 0.04* 16.3 ± 0.13* 1.8 ± 0.01** 1.1 ± 0.01** 3.3 ± 0.07** 4.1 ± 0.21*
NC 10.1 ± 0.09** 30.4 ± 0.19** 2.7 ± 0.08** 9.7 ± 0.13** 6.18 ± 0.06* 2.6 ± 0.06* 5.7 ± 0.15* 10.2 ± 0.12*
DC+HNC 11 ± 0.26* 44.5 ± 0.37* 3.5 ± 0.17NS 15.1 ± 0.55* 1.18 ± 0.08* 1.14 ± 0.04* 1.6 ± 0.06** 4.7 ± 0.13*
DC+HNN 8.5 ± 0.13* 27.3 ± 0.15** 2.4 ± 0.04** 13 ± 0.29* 7.6 ± 0.01** 1.8 ± 0.03** 8.2 ± 0.09* 7.2 ± 0.21*
DC+HNE 8.6 ± 0.13* 33.5 ± 0.11** 2.9 ± 0.07* 14 ± 0.31* 2.4 ± 0.01** 1.7 ± 0.01* 3.6 ± 0.28NS 6.9 ± 0.02**
DC+HNA 12 ± 0.87* 51.4 ± 0.78NS 3.2 ± 0.09* 14.4 ± 0.86NS 1.17 ± 0.09* 1.6 ± 0.01* 2.6 ± 0.25NS 4.8 ± 0.10*
DC+lupeol 8.3 ± 0.08** 23.3 ± 0.23* 2.2 ± 0.08* 13.6 ± 0.09** 8.2 ± 0.09* 2.1 ± 0.06** 10.6 ± 0.05** 7.4 ± 0.08*
DC+Gilb 10.3 ± 0.0.9 31.4 ± 0.13 3.0 ± 0.02 12.1 ± 0.12 6.5 ± 0.01 3 ± 0.04 7.2 ± 0.04 9 ± 0.01
Liver
DC 13.5 ± 0.28* 59.6 ± 0.19** 5.3 ± 0.05** 21.4 ± 0.28* 11.4 ± 0.12* 3 ± 0.01** 3.2 ± 0.04** 4 ± 0.20*
NC 11.1 ± 0.12* 35.1 ± 0.12** 3.3 ± 0.05* 15.9 ± 0.34* 13. ± 0.04** 5 ± 0.03** 4.7 ± 0.06** 11.7 ± 0.36*
DC+HNC 13.7 ± 0.21* 62.07 ± 0.49* 4.5 ± 0.04** 19 ± 0.29* 11.7 ± 0.09** 1.5 ± 0.04** 1.6 ± 0.07* 4.6 ± 0.12*
DC+HNN 11.7 ± 0.35* 43.5 ± 0.13** 3.8 ± 0.11* 16 ± 0.29* 15.2 ± 0.08** 4.8 ± 0.03** 7.1 ± 0.03** 7.7 ± 0.09**
DC+HNE 11.9 ± 0.65NS 50.9 ± 0.15** 4.2 ± 0.02* 16.9 ± 0.23* 11.2 ± 0.06** 4.3 ± 0.04** 2 ± 0.02** 6.7 ± 0.01**
DC+HNA 13.3 ± 0.79NS 53 ± 0.82NS 4.3 ± 0.05** 17.3 ± 0.32* 6.6 ± 0.44NS 2.5 ± 0.01** 2.7 ± 0.10* 4.5 ± 0.45*
DC+lupeol 11. ± 0.07** 35.1 ± 0.08** 3.7 ± 0.02** 15.1 ± 0.17** 15.7 ± 0.17* 5.0 ± 0.11* 8.3 ± 0.09* 8.9 ± 0.02**
DC+Gilb 11.9 ± 0.06 37.3 ± 0.12 3.5 ± 0.01 16.7 ± 0.12 13.4 ± 0.06 5.2 ± 0.01 4.3 ± 0.01 10.5 ± 0.02
Kidney 
DC 11.5 ± 0.07** 60.5 ± 0.18** 4.1 ± 0.04** 20.1 ± 0.31 * 9.8 ± 0.08** 1.2 ± 0.03** 1.4 ± 0.01** 2.5 ± 0.15*
NC 9.5 ± 0.20* 29.9 ± 0.49* 3.6 ± 0.06** 15.8 ± 0.19** 12.3 ± 0.34* 3.7 ± 0.15* 4.2 ± 0.10** 9.2 ± 0.09**
DC+HNC 11.4 ± 0.21* 57 ± 0.82* 3.9 ± 0.04** 19.3 ± 0.25* 10.2 ± 0.11** 1.3 ± 0.08** 1.6 ± 0.04** 4.2 ± 0.34*
DC+HNN 9.8 ± 0.04** 29.2 ± 0.49* 3.3 ± 0.05** 15.5 ± 0.13** 13.0 ± 0.16** 2.3 ± 0.01** 2.8 ± 0.05** 8 ± 0.01**
DC+HNE 11.0 ± 0.08** 50 ± 1.77NS 3.8 ± 0.04** 19.2 ± 0.10** 13.2 ± 0.10** 2.3 ± 0.02** 2.7 ± 0.06** 7.6 ± 0.02**
DC+HNA 11.1 ± 0.06** 50 ± 0.51* 3.9 ± 0.06** 17 ± 0.19** 7.6 ± 0.09** 2.1 ± 0.04** 2.0 ± 0.07** 5.2 ± 0.37*
DC+lupeol 9.7 ± 0.18* 27.1 ± 0.13** 3.2 ± 0.02** 13.5 ± 0.15** 13.1 ± 0.11** 2.8 ± 0.02** 4.0 ± 0.03** 8.8 ± 0.03**
DC+Gilb 10.2 ± 0.08 31.1 ± 0.15 3.7 ± 0.05 16.5 ± 0.11 14.1 ± 0.18 4.3 ± 0.02 3.0 ± 0.01 8.2 ± 0.04
Where “NC” is normal control, “DC” is diabetic control, “HNC” is H. nepalensis crude extract, “HNN” is H. nepalensis 
n-hexane fraction, “HNE” is H. nepalensis ethyl acetate fraction, “HNA” is H. nepalensis aqueous fraction and “Gilb” is 
glibenclamide served as positive control. Values are * p < 0.05 and ** p < 0.01 statistically significant as compared to positive 
control group expressed as means ± SEM whereas NS represents non-significant.
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Estimation of antioxidant level treated 
with H. nepalensis and lupeol
Diabetes mellitus induced by alloxan significantly 
reduced antioxidant enzymes (CAT, POD, SOD and 
GSH) level as presented in Table III. The results depicted 
the positive effect of H. nepalensis extract and fractions 
on these antioxidant enzymes. The treatment of these 
extracts restored the level of enzyme to normal values 
(Table III). Glibenclamide improved CAT activity. The 
treatment of HNN and lupeol increased the activity upto 
78% as compared to diabetic control. In SOD assay, the 
increase in enzyme activity was recorded upto 47.2%. 
SOD activity was decreased in diabetic control liver 
(39.9%) and pancreas (57.1%) with significant increase 
in activity of 36.9% in liver and 40% in pancreas, in 
HNN treated group. Similarly, SOD and POD activity 
was decreased in liver, kidney and pancreas in alloxan 
treated groups. In glibenclamide, HNN and lupeol 
groups, the SOD and POD activitied were significantly 
(p < 0.05) increased (Table III). The decrease in GSH 
activity in alloxan treated experimental condition was 
significantly improved in liver and pancreas (42.3%) 
in HNN and lupeol groups. Overall, results showed 
that CAT, POD, SOD and GSH levels were increased 
significantly (p < 0.05) by H. nepalensis and lupeol 
treatment in diabetic rats.
Histopathological analysis
Effect of H. nepalensis on liver, kidney and pancreas 
histology in different groups is illustrated in Figures 
4-6. Pancreatic histological examination (Figure 4) 
of normal control showed normal islet of Langerhans 
(IL) with constant number of beta cells while diabetic 
control group showed destructed IL cells with scarcity 
of beta cells and large necrosis (N). HNC, HNE and 
HNA groups displayed nearly identical physiology as 
compared to diabetic control. In contrast, HNN and 
lupeol groups showed normal tissue physiology of 
pancreatic tissues with constant number of beta cells. 
Histological pattern of diabetic liver (Figure 5) showed 
sinusoidal dilution (SD) with scattered inflammation 
(SI) along with non-demarcated hepatocyte (HC-
NDM) and nuclear joining (NJ) characteristics of 
disease condition. The groups of normal rats, HNN, 
lupeol and glibenclamide showed nearly identical 
results of intact central venule (CV), hepatocytes 
(HC) and sinusoidal space (SS). Physiology of normal 
kidney (Figure 6) showed average bowmen capsule 
(BC) size whereas diabetic rats showed increased BC 
size with couple of interstitial blood vessels (IBV) 
along with fatty density (FD). The HNC, HNE and 
HNA grouped showed same results as diabetic control 
group. But HNN, lupeol and glibenclamide groups 
exhibited improvement in physiology of kidney tissue 
comparable with normal control. Alloxan-induced 
diabetic rats produced sinusoidal dilation and necrosis 
which were cured by the extract treatment. This could 
have resulted from the capability of the extract to 
enhance antioxidant activities. 
DISCUSSION 
Oxidative stress is thought to be the major cause in 
development and pathogenesis related to complications 
of DM. Liver functions tests are regularly prescribed by 
physicians to monitor the progression of known diseases 
(Atasoy et al., 2007). Hepatoxicity is accentuated cause 
of DM. Elevated ALT, AST, total protein and total 
bilirubin in alloxan treated diabetic control coincide with 
previous observation that diabetic patients usually tend 
to have high transaminases activity (Ahn et al., 2014). In 
the current study, substantial decrease in activity of liver 
function tests such as AST, ALT, total bilirubin and total 
protein after treatment with HNN and lupeol mainly 
attributed to defence of intracellular enzyme leakage 
and cellular stability. This has been reported for other 
ethnopharmacologically important antioxidant plants 
(Thabrew, Joice, Rajatissa, 1987).
Reactive oxygen species associated with oxidative 
destruction are counteracted by different defense 
mechanisms such as SOD, CAT, POD and GSH (Tiwari 
et al., 2013). In present study, the treatment of alloxan 
triggered reduction in activity of SOD, POD, CAT and 
GSH, and increase in TBARS levels led to decrease 
in antioxidant protection potential (Tiwari et al., 
2013). However, HNN and lupeol treatment produced 
promising increase in activity of SOD, POD, CAT 
and GSH in liver and pancreas. CAT, SOD and those 
compound having hydroxyl radical scavenging property 
antagonist to alloxan; provide the indication that alloxan 
illicit its action by superoxide anion and hydroxyl radical 
(Grankvist et al., 1981). HNN and lupeol produced effect 
by scavenging reactive oxygen species, either due to 
existence of diverse antioxidant compounds or through 
increasing biosynthesis of antioxidant compounds 
(Santiago, Mayor, 2014). 
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FIGURE 4 - Histology of the pancreas. (I) normal control, 
(II) diabetic control, (III) HNC, (IV) HNN, (V) HNE, (VI) 
HNA, (VII) lupeol and (VIII) glibenclamide. Samples were 
magnified at 40X and “IL” is Islet of Langerhans, “N” is 
necrosis and “FN” is focal necrosis. 
FIGURE 5 - Histology of the liver. (I) normal control, (II) 
diabetic control, (III) HNC, (IV) HNN, (V) HNE, (VI) HNA, 
(VII) lupeol and (VIII) glibenclamide. Samples were magnified 
at 40X and “CV” is central venule (CV), “HC” hepatocytes, 
“SS” sinusoidal space, “SD” is sinusoidal dilution, “SI” is 
scattered inflammation, “HC-NDM” is non-demarcated 
hepatocyte, “NJ” is nuclear joining and “N” is necrosis. 
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FIGURE 6 - Histology of the kidney. (I) normal control, (II) 
diabetic control, (III) HNC, (IV) HNN, (V) HNE, (VI) 
HNA, (VII) lupeol and (VIII) glibenclamide. Samples were 
magnified at 40X and “BC” is bowmen capsule, “IBV” is 
interstitial blood vessels and “FD” is fatty density. 
Lipid peroxidation causes oxidative stress that is 
mainly attributed to the chronic stage of DM (Elangovan 




 and nitrite 
level increased in alloxan treated experimental control, 
due to the fact that alloxan damages β-cells of pancreas 
by producing reactive free radical species. This results 
in membrane damage due to glycation and peroxidation 
of protein and lipid, respectively (Baynes, 1991), and 
leads to increase in blood glucose level. Treatment with 





 and nitrite. This observation may be due to the 
fact that destructive effect of O2• and OH• radical is 
counteracted by the component of antioxidant defense 
system like SOD, CAT and GSH and they help to 
neutralize or eliminate the effect of free radical oxygen 
species. Strong evidences have shown the role of reactive 
oxygen species (ROS) in DM and many experiments 
have shown the destruction of tissue in DM (Kakkar 
et al., 1995). Under normal circumstances, antioxidant 
system of body protects against the free radical species 
generated during chronic diabetic stage in vivo.
In present study, amplified nitrite level clearly 
depicted the role of nitric oxide (NO) free radical pool 
generated in pancreas of diabetic control. NO produced 
by β-cells of pancreas, in treatment with alloxan, has been 
associated in the advancement of diabetes (Sentman, 
Josson, Marklund, 1999). The role of NO, ROS and 
peroxynitrite-derived species (NO+ superoxide anions) 
in diabetes has been shown in streptozotocin-induced 
diabetic rats with increased activity of NO in kidney 
(Stadler et al., 2003).
Lupeol activity at the dose of merely 3 mg/
kg BW was noted to be greater than glibenclamide 
(5mg/kg bw) in provoking hypoglycaemic response 
in alloxan induced diabetic control. Both HNN and 
lupeol increased insulin level to 452.5% and 820.6%, 
respectively as compared to diabetic control. Lupeol 
group showed 3.95% higher insulin concentration 
than glibenclamide treated group. Some observations 
supported the role of lupeol as blocker of α-amylase 
activity, and therefore conclude that inhibition of 
α-amylase is feature of the triterpenoid structure 
(Ali, Houghton, Soumyanath, 2006). We previously 
reported the highest flavonoid and phenolic contents in 
HNC and HNE extracts, catechin and caffeic acid in 
HNA and HNE respectively, and rutin and chlorogenic 
acid in crude extracts of H. nepalensis (Inayatullah 
et al., 2012). Flavonoids have anti-hyperglycemic 
activity (Cho et al., 2010), act as inhibitors of DPP-4 
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(Parmar et al., 2012), and help improve the glycemic 
status in animal models. 
To sum up, the data reflected in alloxan treated 
rats exhibited following responses: (1) HNN and lupeol 
significantly reduced plasma glucose level, (2) HNN or 
lupeol treatment increased the oral glucose tolerance, (3) 
a protective effect was seen against diabetes related liver, 
pancreas and kidney injuries after treatment with both 
HNN and lupeol, and (4) most important and promising 
results of HNN and lupeol was enhanced insulin levels 
after treatment in dose dependent and time dependent way. 
We show that H. nepalensis can ameliorate the symptoms 
of diabetes and regulate the glucose metabolism. Its 
antioxidative properties protect the liver, kidney and 
pancreatic tissue against diabetogenic injury. Although 
H. nepalensis showed significant anti-hyperglycaemic 
activity, it also has ability to enhance de novo insulin 
production. This plant could be future potential therapeutic 
medicinal plant against diabetes and its related disease. 
COMPETING INTERESTS
Authors declare no conflict of interests 
regarding the publication of this paper. 
AUTHOR’S CONTRIBUTIONS
HI and WJH conducted all the assays and 
experimental work. BM conceived the study design and 
supervised the study. LJ contributed in study design 
and isolated lupeol previously. HI and WJH drafted the 
manuscript and all authors proof read the final version.
ACKNOWLEDGMENT 
Authors acknowledge the animal ethical committee 
for approving to wrk on rat models and the technical 
staff for their help and support during execution of this 
project. Authors greatly acknowledge the Biological 
Manuscripts Editing Services (BioMES) of Alpha 
Genomics Private Limited, Islamabad, Pakistan, for 




HNC: H. nepalensis crude extract
HNN: Hedera nepalensis n-hexane fraction 
HNE: Hedera nepalensis ethyl acetate fraction 
HNA: Hedera nepalensis aqueous fraction 
OECD: Organization for Economic Cooperation and 
Development
NC: Normal Control, non-diabetic
DC: Diabetic Control
BW: Body weight 
ELISA: Enzyme-linked immunosorbent assay
ALT: Alanine transaminases
AST: Aspartate transaminases 
CAT: Catalase
SOD: Superoxide dismutase 
GSH: Reduced glutathione
POD: Peroxidase 
BUN: Blood urea nitrogen 
TBARS: Thiobarbituric acid reactive substances
ROS: Reactive oxygen species
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